text:
AIDS Treatment News
Crixivan(R) Price Break for Cash Customers:
After extensive protest against the large markup on Merck's protease inhibitor (from $12 per day which is Merck's price, to the $16.50 per day retail price for cash customers), Stadtlanders Pharmacy has found a way to reduce the cash price from $16.50 to $13.27 (consistent with it contractual obligations to insurance companies and managed-care plans, which already get discounted prices). They will do this by honoring a discount card which has long been provided by another mail-order pharmacy, Community Prescription Service (CPS). The CPS card costs $18, and is honored by about 60% of pharmacies in the U.S., who give a negotiated below-retail price to card holders, not only for Crixivan.
Note: Due to a special temporary distribution program for indinavir (Crixivan), described in AIDS Treatment News #244, April 5, 1996, most patients can only order this drug through Stadtlanders.
It appears to be most convenient if you get the card in advance directly through CPS. For more information, or to order the discount card, call CPS at 800/842-0502. But you can also ask for the card when you call Stadtlanders for your monthly Crixivan prescription; they can order it for you from CPS and give you the discount immediately.
This program was announced on April 18, and largely negotiated the day before. It may take a few days or more for Stadtlanders' phone operators to be told about the program and trained in how to use it.
Note: The reason for this price irrationality is that there has to be a "retail" price substantially higher than the negotiated discount prices which large institutions pay.
Protease Inhibitors:
The first trial to combine protease inhibitors is now recruiting 120 volunteers in seven sites in the U.S. and Canada. This study is being conducted by Abbott Laboratories, Inc.
There is much interest in combining these two drugs, for several reasons -- but there are also potentially serious safety concerns. Saquinavir is quickly eliminated from the body, making it hard to get sufficient blood levels with the currently approved drug formulation; ritonavir, given with saquinavir, can produce increased and sustained levels of saquinavir because it slows the process used by the body to eliminate saquinavir. Also, the drugs have very different resistance patterns, which may work together well to slow the development of viral resistance to the combination.
But this combination must be tested very carefully. Correct dosing must be used when combining these drugs -- and the doses are not yet known. Blood levels of saquinavir become higher than previously achieved, and the safety of saquinavir at these blood levels is unknown. In addition, if doses are too low, viral resistance could develop. To help avoid these problems, blood levels will be measured in this trial, using a test which is not commercially available.
To be eligible, you must be at least 12 years old, have a CD4 count of 100 to 500, have never taken any protease inhibitor, have no acute opportunistic infection nor inflammation of the pancreas, and not be taking any medication contraindicated with ritonavir. You can be using other approved antiretrovirals (AZT, etc.), but will have to stop them two weeks before beginning treatment in this trial.
For more information about these trials, call Mabrey Whigham at the International Association of Physicians in AIDS Care, 312/419-7295. Or for the San Francisco trial, you could call the HIV Institute at Davies Medical Center, 415/565-6222. We could not determine the other cities before going to press.
Protease Inhibitors:
One of the best information sources on protease inhibitors continues to be the National AIDS Treatment Advocacy Project (NATAP). You can obtain its written report, get the most current information from its Web site, or obtain videotapes of two major community meetings which NATAP has held so far, in New York (January 26) and Los Angeles (April 13).
Los Angeles Meeting
About 700 people -- apparently a record for any AIDS medical meeting in Los Angeles -- filled the Paramount Pictures Theater on a Saturday afternoon, April 13, for "Protease Inhibitors: Current and Future Use," a free educational forum organized by Jules Levin of NATAP, along with over 15 Los Angeles AIDS organizations. The theater was still full three hours after the program started.
Perhaps the most important theme of the Los Angeles meeting was the need to follow medical advice and use these drugs properly. "Drug holidays," arbitrary dose reductions, and other misuse create windows of opportunity which can help the virus become resistant to the drugs. Once resistance develops, it is probably permanent, and one or more of the protease inhibitors will be less valuable to the patient in the future.
Note that some protease inhibitors must be taken on a full stomach, and others on an empty stomach, to be absorbed effectively. Physicians can give instructions on what is and what is not acceptable.
For persons beginning treatment with the Abbott protease inhibitor ritonavir (Norvir(TM)), Abbott is recommending a dosage ramp-up approach, in which slightly lower doses may be used for the first few days. This dose adjustment may help the body adapt to ritonavir by gradually introducing the drug into the blood. It may reduce unpleasant side effects which some (though not all) patients experience, especially during the first two weeks. Abbott does not expect this approach to increase drug resistance.
It is essential to follow medical advice about not combining the Abbott protease inhibitor with many other common drugs. Some of these drugs can cause life-threatening reactions if combined with ritonavir.
There are fewer side effects and drug interaction problems with the other two approved protease inhibitors, indinavir (Crixivan) and saquinavir (Invirase(TM)). But interaction and other safety precautions must be followed with these drugs too.
Meeting Organizers Note
Persons organizing AIDS meetings should note some of the factors which led to the large attendance of the protease inhibitor symposium in Los Angeles, a city where people are unlikely to come to AIDS meetings. (1) The topic was urgently important, as many people are starting these drugs and need information. (2) The symposium had very good support from local AIDS organizations, some of which mailed the flyer to their clients. (3) Volunteers carried flyers to HIV medical practices and clinics, coffeehouses and bookstores, and other appropriate locations. (4) Meeting organizer Jules Levin came to Los Angeles several days in advance to work full time on the arrangements.
Delavirdine Available
Persons with a CD4 count of 300 or less who are failing other therapy may qualify for an open-label program to use the experimental antiretroviral delavirdine in combination with at least one other antiretroviral.
To be eligible, patients must not be hospitalized, or have "an acute, serious, life-threatening condition," or be treated concurrently with rifampin, rifabutin, astemizole, loratidine, or terfenidine. Patients must not have hemoglobin less than 8.0, neutrophils less than 600, platelets less than 25,000, or creatinine greater than 3.0. There are some additional entry criteria.
Your physician can register you for the program by calling 800/779-0070. Some paperwork will be required, and possibly local IRB approval. This program has already been approved by a national IRB.
For more information, persons in the U.S. and Canada can call 800/432-4702 or 800/779-0070.
Sinusitis: Helpful Background,
A useful background article on sinusitis was published in the March 1996 issue of BETA (BULLETIN OF EXPERIMENTAL TREATMENT FOR AIDS), a treatment newsletter published by the San Francisco AIDS Foundation. "Sinusitis," by Leslie Hanna of the Foundation, looks at causes, symptoms and diagnosis, and various different antibiotic and other treatments -- including acupuncture, herbal treatments and holistic interventions.
San Francisco residents may pick up a free copy of BETA at the San Francisco AIDS Foundation, 10 UN Plaza, at the Client Services Waiting Room on the 2nd floor. Others may call BETA at 415/487-8060 to get a copy or a reprint.
Subscriptions to BETA cost $75 (institutional rate $165), and can be ordered by calling 800/959-1059.
Chinese Medicine:
For several years Emilio Gonzalez and George Wedemeyer have been leading classes in Qigong, a form of exercise used in traditional Chinese medicine. The classes, for people with HIV or other chronic diseases, request a nominal donation of $1. Now the instructors, both long-term AIDS survivors, have produced a four-week Qigong class on videotape, with help from video professionals who volunteered for this project. All proceeds from the sale of the tape will support direct client services at the Immune Enhancement Project (IEP), an acupuncture clinic in San Francisco. (For an interview with Tom Sinclair, L.Ac., executive director of the Immune Enhancement Project, see AIDS Treatment News #230 , September 1, 1995.)
The two-tape set, with four lessons totaling two and a half hours, can be ordered for $59.95 from the Immune Enhancement Project, 3450 16th St., San Francisco, California 94114, 800/835-6555 or 415/252-8711, fax 415/252-8710.
For more information about the San Francisco classes, call George Wedemeyer, 415/975-4561 or Emilio Gonzalez, 415/255- 0265. Or check the IEP home page on the World Wide Web, http://www.creative.net/~iep -- which also includes a form for ordering the tape by fax.
rGP-160 Treatment Vaccine (VaxSyn):
A multi-center trial in Canada, which gave either recombinant GP-160 or placebo to 278 volunteers with HIV during a three- year study, found "no clinical benefit from this product nor any usefulness in maintaining immune competence," according to Chris Tsoukas, M.D., of Montreal General Hospital. Dr. Tsoukas noted that these results do not apply to preventive vaccine trials.
The Canadian study was completed in November 1995, but the results were not announced until a similar U.S. study was completed in March.
Only a brief announcement of the negative finding has been made at this time. Detailed results may be available in a few weeks.
This negative result illustrates the need for research in HIV pathogenesis, and particularly in the correlates of immunity. It is easy to produce an antibody response, or other kinds of immune response to HIV. What is much harder is to know what kinds of immune response are protective.
While difficult, this problem is not impossible. Studies of long-term nonprogressors (who have HIV but do not get sick), and of persons who have been repeatedly exposed to HIV and remained uninfected, may help to determine what kinds of immunity are effective in preventing or controlling infection.
FDA Reform in Congress: by John S. James
Legislation to change the U.S. Food and Drug Administration has now been introduced in both houses of Congress. This legislation might become law, and interested parties need to make themselves heard now, as Congress must act quickly on these bills, or it will be too late for this year. Those who are not aware of the issues involved could miss the chance to have a say in decisions affecting them.
For one view on these issues, AIDS Treatment News interviewed Peter Barton Hutt, who is widely recognized as one of the world's leading experts on FDA law. Mr. Hutt has practiced regulatory law for the past 35 years, and served as general counsel of the FDA between 1971 and 1975. He is now in private practice at the Washington D.C. law firm of Covington and Burling, and also teaches a course in food and drug law at Harvard Law School.
We told Mr. Hutt that we were especially interested in the earlier stages of the drug development process, as well as in the current legislation.
AIDS Treatment News: Some people are saying that the rapid approval of protease inhibitors shows that FDA reform legislation is not needed, that any problems have already been fixed. What else should these people be aware of?
Hutt: The rapid approval of a number of new drugs shows that where FDA wishes to do so, it can place its resources and can improve the system. The difficulty is that those cases represent ad hoc decisions under a great deal of pressure at one particular point in time, and do not represent a systematic change in FDA procedures and policies. One cannot conclude that these improvements will apply for a longer time to a wider group of therapies.
The drug approval process cannot be viewed in isolation. It is part of an extraordinary lengthy discovery, research, and development process that now takes more than a decade. Only 20 years ago, the process from drug discovery to approval averaged approximately six to at most eight years. Today it is in the area of 15 to 16 years. The time required has roughly doubled during the last two decades.
What has happened is that the FDA has become more stringent overall in its requirements. While the time for APPROVAL has remained the same or diminished slightly, the time for research and development has escalated dramatically, making it take even longer for important new products to reach the marketplace. Therefore, in looking at legislation, one must focus on all aspects of this process, not only on the final decision of approval or disapproval.
ATN: Where in the earlier phases do you think major time savings can and should be made?
Hutt: They must be made in every stage. The first stage is preclinical testing. FDA has requirements that must be met before any drug can be put into a human. These have been relatively stringent and relatively inflexible. If they are made less stringent and more flexible, human trials could start more rapidly.
Second, one must look at the requirements FDA has imposed for submission of an IND application. [Note: An IND -- Investigational New Drug -- application must be approved by the FDA before a new drug can be tested in humans.] If you compare the size and content of an IND in the United States and in Europe, you will see that the one in the United States can be six or eight feet thick, and the one in Europe is six or eight inches. That difference represents an enormous investment of time, resources, and of course money. In Europe you can investigate more drugs than in the United States, because the investment required is less.
Third, when you look at the requirements for monitoring and record keeping, and adverse reaction reporting, in Europe vs. the United States, you understand why more and more clinical trials are being conducted abroad. You can do much more for less money, more quickly and more efficiently, abroad than you can in the United States. The consequence is that some investigational drugs which are available abroad cannot be used for any form of expanded access or compassionate use in this country.
ATN: The cost of new AIDS drugs is now a major issue. Could we reduce drug prices by cutting the cost of development?
Hutt: Time is money. The amount of resources needed to investigate and ultimately bring to approval a new drug depends on time, and also on the complexity of the requirements imposed. Regulatory requirements therefore directly decide the ultimate price of a drug.
ATN: Someone described the current "Good Laboratory Practice" regulations as 40 tons of cure imposed because of isolated instances of abuse.
Hutt: One company submitted fraudulent data on its testing of pesticides and other products. As a result, FDA imposed, in the late 1970s, stringent Good Laboratory Practice record keeping requirements that are enormously costly and burdensome.
Every bit of this contributes to cost and time. The difficulty is that, if you take any one of these issues in isolation, you can find some justification for it. In isolation, you can say, "That only costs so much more." But if you put them all together -- and consider that they have been added one on top of the other for the last 40 years -- you begin to understand the enormous impact.
ATN: How do the bills in Congress now address these problems? [Note: The bills referred to in the following discussion are S. 1477, introduced by Senator Nancy Kassebaum, Republican, Kansas, on December 13, 1995, and H.R. 3199, introduced in the House by Congressman Richard Burr, Republican, North Carolina, on March 29, 1996.]
Hutt: These bills are remarkably close in philosophy and intent. They are written with different words and phrases, but that should not be interpreted as meaning a fundamentally or structurally different approach. They are very similar.
ATN: We reported to our readers when a draft of the Kassebaum bill became available (see AIDS Treatment News #235, November 17, 1995) that this bill focuses on procedures to hold the FDA accountable for its performance, rather than on mandating or micromanaging specific decisions.
Hutt: The same concept occurs in the House bill. That is why I said they are similar in concept. Both bills realized that you cannot focus on just one part of the total discovery, research, development, and approval process. You have to deal with every aspect of that or you will not make a difference.
Each bill has its strength and weaknesses. Let me mention one difference which is important, and may be misunderstood.
The Senate bill contains a provision, a strongly worded statement of philosophy, which says that any patient, through a physician, has the right to request an investigational drug for expanded access treatment use, and any company has the right to provide that. The company does not have an obligation to provide it, but they have the right to do so. That statement does not occur in the House bill, but the House bill clearly provides, without saying it, that the same is true.
My personal preference would be to include this explicitly in the legislation. But it is erroneous to think that the House does not agree with expanded access because it did not include this specific language. I would certainly support an explicit provision of that kind, which gives a flavor, tone, or mandate that otherwise might not be clearly understood.
ATN: But it does not create a new legal right?
Hutt: It is legally unenforceable in both bills, but it is nonetheless a very powerful statement of intent.
ATN: But you think that patient advocates might want to make it clear to Congress that they want the Kassebaum version to prevail in the final legislation?
Hutt: Yes. I believe interested people should make clear to the House that they consider immediately incorporating it into the next version of the bill.
ATN: And they could copy the language right out of the Kassebaum bill?
Hutt: Yes. The language in the Kassebaum bill to my knowledge has not been substantially opposed by anyone -- not by patient groups, not by the industry, not by consumer advocates, not by anyone. It may have been omitted from the House bill only because nobody lobbied the House on it.
Hutt: There is another important provision in the Senate bill that your readers should be aware of, and come to their own decision. Under current FDA regulations, for a drug treatment IND and for all medical devices, a company is permitted to charge for an investigational product. They can charge for the manufacture of the drug, for the cost of research and development, and for the cost of handling. Under the Senate bill, the cost of research and development was deleted.
The first question is, what does that mean? Will the FDA have to delete the cost of research and development from the treatment IND and medical device regulations? I do not believe that is what is intended, but the meaning is quite unclear. The second question is why was that provision deleted, who deleted it, and what was the intent of the Committee? That is unclear to me as well.
If in fact it means that companies would be completely prohibited from taking into account their research and development costs in charging for investigational products, it seems to me highly probably that far fewer companies would be willing to make investigational products available. They would be lucky to break even. Considering the time and effort it takes them to provide expanded access, it would undoubtedly not be worth their effort. In my judgment, this change would substantially reduce the number of investigational products available for expanded assess. People should consider this issue, and whatever their views are, make them known to both the Senate and the House. There is no comparable provision in the House bill.
ATN: What is the timetable for this FDA legislation?
Hutt: The timetable in Congress is tight. There are relatively few legislative days left in Congress this session. Senator Dole, on the campaign trail, did commit to bring this bill to the floor in the Senate, so it is likely that will happen.
ATN: Is Kennedy likely to oppose the bill, or not?
Hutt: The position of Senator Kennedy remains unclear. He voted against the bill in the Senate markup, but three Democrats voted for it. There are attempts to achieve compromise to make it less likely that he will oppose it. It is entirely uncertain what his ultimate position will be.
ATN: Is Kennedy concerned about allowing pharmaceutical companies to talk about off label uses of drugs?
Hutt: That provision was deleted from the Senate bill in the markup, because the Committee could not reach a consensus on exactly what it should say. There are efforts now to reach a compromise and put that provision back into the bill.
ATN: What are Kennedy's main objections at this point?
Hutt: That is a very long story. It appears that every time one of his objections is met, he comes up with a new objection on a different provision. There is some concern that there is an endless list that would gut the entire legislation if it were met.
ATN: Do you think the FDA wants to conduct a war of attrition against the bill through Senator Kennedy?
Hutt: In one syllable, yes. This is not a surprising strategy. The FDA is totally opposed to the entire legislation. There is nothing in the bill that is acceptable to FDA. It will do whatever it can to delay the bill or defeat it.
ATN: What can individuals and organizations do to get their views heard and considered on these issues, at this late time?
Hutt: People should work through their organized groups, which are singularly the most effective way of making their views known, as well as getting in touch with their own personal representatives in the Senate and the House. Working through organized groups that are in Washington, and can monitor the progress and the changes that are made, is always the most effective way to proceed.
FDA Reform in Congress: by John S. James
Perhaps the best case against major elements of the FDA reform legislation now being considered by Congress is the February 21, 1996 testimony of FDA Commissioner David A. Kessler, M.D., before the Senate Committee on Labor and Human Resources -- chaired by Senator Nancy Kassebaum, Republican, Kansas, who introduced S. 1477. It is impossible to meaningfully summarize this statement, which is 48 pages double spaced plus 19 pages of attachments. But we want to give our readers a sense of some of the concerns. (Note: Kessler's testimony addressed only S. 1477; H.R. 3199 had not been introduced yet.)
Dr. Kessler urged Congress to consider the progress in rapid drug reviews and other areas that has been made in the past several years. "If we are to achieve our shared goals of improving the Agency's ability to protect and promote the public health, we must base our work on FDA's current performance. Unfortunately, too many of our critics justify the call for 'reform' based on how the FDA did its job in the 1980s or earlier. They have missed the substantial progress that the dedicated doctors, nurses, engineers, chemists, microbiologists, biostatisticians, nutritionists and others at the FDA have achieved over the past several years. They would have us ignore the important lessons that we have learned about the kinds of change that will result in getting safe and effective drugs and devices to the market more quickly. Those who fail to recognize the Agency's performance and achievements threaten -- intentionally or not -- to undermine the real progress the Agency has made. Undermining progress in critical public health and consumer protection is not 'reform.'"
Dr. Kessler pointed out that according to a study by the General Accounting Office (GAO), the average time for approval of new drug applications was 33 months for applications submitted in 1987, but reduced to 19 months for those submitted in 1992. This, he noted, was largely due to user fees for prescription drug approvals -- a system created by Congress in 1992, with the approval of the pharmaceutical industry. Under this system, companies pay to have their applications processed by the FDA -- which uses the money to increase staff and other resources to get the applications handled more quickly. This system included performance goals for the FDA, which has already met the 1997 goal for reduced review time, three years ahead of schedule.
Kessler cited extensive comparisons between drug approval times in the U.S., the UK, Germany, and Japan -- making a strong case that the U.S. now has the fastest drug approvals of the four.
But Dr. Kessler was concerned about the requirement of S. 1477 that by July 1998 the FDA would review all drug approval applications within 180 days, and priority drugs within 120 days. "I do not believe that the Agency could meet the product review times set forth in S. 1477, with existing resources, without compromising existing public health protection...
"What does it take to review an application within four to six months? First, it takes an excellent application. With only four to six months there would be little opportunity to obtain clarifications or additional information from the sponsor. Although every application could be reviewed exactly as it is submitted, very few applications are so complete and accurately presented as to be approvable without further discussion with the sponsor. Second, it requires having the necessary review staff, including all the various disciplines, ready to work on the application the day it comes in the door. That means other work needs to be put on hold. Third, it means companies will need to be fully ready to manufacture the drug... Fourth, the shortened review times will compromise the effectiveness of advisory committees...
"Under the S. 1477 timeframes, the Agency also would be required to limit its involvement in the production and post- approval areas... In fiscal 1995, there were 251 product recalls."
"Shortening the review times also will adversely impact Agency programs that are NOT related to drugs or other product approval process, such as the safety of the blood supply, food safety and tampering, and mammography quality. Our efforts to protect the public from unsafe imported products -- whether it is botulism-contaminated mushrooms or hepatitis-contaminated human tissue, will have to be curtailed. It will also severely curtail our ability to respond appropriately to emerging public health threats, crises, or even to new areas where a little work would have a large payoff."
Kessler outlined many other concerns:
"There are several sections of the bill that would establish new and lower product approval standards. For example, Section 407 would establish a new process for approving new uses of existing drugs that would completely bypass the drug approval process. It would establish a procedure for recognizing new uses based on medical practice... This provision moves us away from the accepted scientific standard of evidence back toward evidence based solely on anecdotal experience..."
"We are also concerned that the bill would eliminate FDA's role in assuring that modifications made to a product do not adversely affect its safety and effectiveness. Under the bill, unless the manufacturer's own data show that safety and effectiveness were to diminish, FDA could not require data on the modified product (Sections 702 and 707). Yet we know that such modifications can carry initially unrecognized risk..."
"We are equally concerned that the bill would remove even the basic assurance that most new devices will be well made. Under Section 702 a company, even one with known manufacturing problems directly relevant to its new device, would have to be given marketing approval even though the Agency has evidence the firm is unable to produce a quality product..."
"There are a number of provisions throughout the bill which would allow companies to market products without FDA approval, if the Agency fails to meet review deadlines..."
"The bill's requirement for third party review is equally troubling... FDA's scientists and experts are charged with exercising independent and unbiased judgment. They comply with stringent financial disclosure and conflict of interest requirements designed to protect the decision-making process against bias. It is not clear whether, and how, this independence can be maintained with private sector review organizations...
"The substitution of judgment also extends to the manufacturing area. When a contractor has given a manufacturer good marks for its production process, FDA is prohibited from inspecting the plant for two years unless the Agency learns through other means that there is something seriously wrong at the plant."
Other concerns involve expanded access -- now available through FDA regulations, which would be legislated instead, beyond the FDA's control:
"Unfortunately, S. 1477 (Section 202) would permit drug and device companies to side-step completely FDA's approval process and go into the manufacture, promotion, and sales of a product for any serious disease or condition without FDA approval. Under S. 1477's provisions, expanded access protocols could be given for any product that diagnoses, monitors, or treats a serious disease or condition, so long as other therapy is not 'comparable or satisfactory.'
"In addition, S. 1477 would permit the manufacturer to widely promote the availability of the expanded-access protocol (Section 202). Unlike FDA's current system for cost recovery under a treatment IND, there is no requirement in the bill that adequate enrollment be obtained for clinical trials that are designed to determine the safety and effectiveness of the product, and that the manufacturer pursue marketing approval with due diligence. In short, the patient would have to pay full price for an experimental product, and the company would be under no obligation to ever find out its true value. Coupled with the provision for cost recovery, promotion of the availability of experimental treatments would create a climate where the unscrupulous could sell untested hope with scant risk of being found out and only weak sanctions if they were. The 1995 Health and Human Services Inspector General's review of commercialization of unapproved medical devices shows this is not just a theoretical risk but a predatory business practice hard to control even with today's stronger law."
Off Label Drug Information
Major controversy exists about whether pharmaceutical companies should be allowed to promote "off label" uses of approved drugs -- that is, uses which have not specifically been approved by the FDA. The FDA realizes that off label drug uses can be appropriate and beneficial. But at present, a pharmaceutical salesperson cannot give a physician a peer- reviewed journal article about an unapproved use of the company's product, unless the physician asks for it.
Kessler did not address this issue, but left it to William B. Schultz, Deputy Commissioner for Policy, to present the FDA's position to the Senate Committee on Labor and Human Resources, on February 22, 1996. Schultz described a number of cases where allowing companies to promote off label uses would have led to serious harm.
We have not seen a similarly detailed case in favor of changing the current law. Such a document is needed, because this issue requires a judgment call. The examples cited by Schultz must be balanced against the damage caused by poorly informed physicians who do not read the literature or who find it safer for their careers to avoid initiative, and provide poor treatment to patients when better treatment is possible.
Schultz also described major FDA initiatives to reverse certain problems at the FDA in the past, and make it much easier for companies to get new indications onto the label. He noted that many off label uses could be approved with no new clinical trials, if companies would just copy existing data and submit them to the FDA. And the FDA is now working with leading physicians to identify the most important off label uses, in order to work with companies to get them approved.
Our goal in reporting the controversy about Congressionally- mandated FDA reform has been to expose our readers to leading advocates of both sides, and to the complexity of the issue. Those who work seriously in this area will need to study and listen to differing views. So far the custom has been to hear one side, and demonize the other.
The remarkably articulate and compelling arguments on both sides are only a beginning to understanding in this area. On closer look, both leave much to be desired. Hutt addresses easy issues of the current legislation. Kessler addresses hard ones, but questions remain.
For example, it could be argued that a "climate where the unscrupulous could sell untested hope" might ultimately save many more lives than the climate we have. For excluding "untested hope" has also largely excluded all contributions except from big business -- shutting out small companies, which are often the most creative, but which have to sell out to the big ones. (It is no accident that the driving force behind the current FDA-reform legislation is the medical- device industry, largely consisting of entrepreneurial companies far smaller than the huge corporations of the pharmaceutical industry.)
And also largely excluded is every medical tradition on Earth except for one -- the one which has developed only in the last several decades but has used its money to dominate Western institutions, especially in the U.S. This dominant tradition is increasingly based on formal evidence -- perhaps a major advantage -- but also it is notably crude, inefficient, narrow, and cruel in its methods of gaining knowledge. A better public policy might be to open the door somewhat wider, trusting more in the judgment of patients and physicians, judgment which of course includes formal evidence when available, but also includes other evidence not formalized yet. Yes, quacks will use the opening; but nothing eliminates quackery faster than treatments that really work. And it is preposterous to think that the best way to find treatments that work is to eliminate all of the human race except for the narrowest elites from any real role in medical development.
The most central issue, we believe -- beyond anything Congress does this year -- is how to make medical research and drug development work better. We fear that neither side in the politically charged debate has a useful answer. For decades, an FDA controlled by Democrats in Congress piled rule upon rule in the name of public safety, oblivious both to financial costs, and to the human costs of research stagnation. Now Republicans control Congress, and industry believes its day is here, and wants its reward. Both ideologies are a disservice to the public.
Perhaps the best we can hope for immediately is what has already been happening so far -- no new law, but the FDA so afraid of one that it does more than seemed possible to improve itself from within.
We believe that the key bottleneck in medical research is the difficulty of obtaining the first credible data in human testing of a new idea or approach. Senator Kassebaum's office chose NOT to address this issue in S. 1477 -- probably because the most visible proposal for doing so (letting institutional review boards bypass the FDA and approve human trials) clearly has drawbacks. No one knows how to balance safety and progress at the edge of creativity and the unknown. Perhaps there is no systematic way.
The current debate has been productive in stimulating FDA reform. It could be equally valuable if it shakes official Washington out of its traditional ignorance and disinterest in the obstacles to medical progress, and the opportunities to do better.
For More Information
Vancouver Conference:
The program of the XI International Conference on AIDS (Vancouver, July 7-12, 1996) has been built around the abstracts submitted. Since the abstract deadline was February 1, and it took time to review and categorize the submissions, the major scientific issues which the conference will address are only now coming into view. Some of the areas which will receive most attention are:
A record number of abstracts -- 5,626 -- were submitted to this conference; this is more than for any other conference except Berlin, which allowed individuals to be presenting author for more than one abstract. About 90% of the Vancouver abstracts were accepted.
Plenary Program
The plenary program -- the talks and debates addressed to everyone at the conference -- is now as follows:
Travel, Media Arrangements
It is important to make travel reservations now, due to limited space in hotels and in flights into Vancouver.
Media persons must be accredited to cover the conference, and are strongly urged to take care of that now, due to limited hotels in Vancouver.
Contact Greg Hamara (see Contact Information, below).
Skills Building Meetings, July 8-11 Afternoons
"Managers, trainers, programmers, volunteers, and clinicians from developing countries are encouraged to participate with professional facilitators and experienced community based practitioners. The workshops will examine analytical tools, low cost technology and the experience of participants to find new personal and group resources for dealing with challenges of community based organizations."
Topics include assessing community needs, interactive training techniques, managing nutrition in the face of poverty, CD4 testing alternatives, writing a funding proposal, and many others.
For more information, contact Peter Gillies, Skills Building Coordinator, fax 604/668-3242, email firstname.lastname@example.com, or email@example.com.
Community Forum 96, July 5-6
"Community Forum 96 is an international gathering of persons living with HIV/AIDS and community organization workers that will precede the XI International Conference on AIDS. Over a period of two days, this working meeting will bring together 500 persons -- 100 from each of the five regions of the world..."
For more information, contact the Community Liaison Department of the Conference Secretariat; see contact information below.
Satellite Meetings
Organizations and companies have scheduled the following satellite programs. Because of limited space, we have only listed the date, the sponsoring organization, and the title of the meeting, to help people plan their schedule and make travel arrangements. Time and place of these meetings, as well as contact persons and phone/fax numbers, are usually available from the conference site on the World Wide Web, http://www.interchg.ubc.ca/aids11/AIDS96.html.
Friday July 5
Saturday July 6
Sunday July 7 - Friday July 12
Many additional satellite meetings could not be listed here due to lack of space; we will publish them in our next issue. We included the pre-conference meetings now because they are most likely to affect travel plans. The later satellite meetings occur on the days of the conference itself.
Contact Information
Conference Secretariat, XI International Conference on AIDS, 11th floor, 1090 West Pender, Vancouver, British Columbia, Canada V6E 2N7; phone 800/780-AIDS, or 604/668-3225; fax 604/668-3242;
email firstname.lastname@example.com;


text:
Sometimes when a teacher talks a student is listening but not hearing, and that means they're not learning.
Oiseal Nunez had that problem a lot. The answer for him-- Mike Fusco.
Nunez is a 9th grader at Oak Ridge High School and Fusco is a tutor here, but not just any tutor. Fusco is a City Year Corps member.
The name City Year essentially explains what the group is and what he does.
After college, Fusco is now volunteering one year of his life at a city school before he goes in to teaching full time.
"I saw all these students slipping through the cracks and it solidified it wasn't really right for me and as a teacher you can't reach every single student, and I was really bummed out about that," said Fusco.
City Year Corps members work with teachers to figure out which kids need one on one help.
At Oakridge High School there are ten corps members, who each have about ten students to help.
But they are also available in the classroom for anyone to ask for help. They also have their own office at the school, so any student can seek them out.
City Year is in five Orange County schools including elementary and middle schools.
At Oakridge High they specifically target 9th graders.
"Ninth grade is really the make or break year. For many students if we can get 'em through the 9th grade year so they have a successful 9th grade, establish positive patterns then their likelihood of success increases dramatically," said Oakridge Assistant Principal Osvaldo Piedra.
Nunez was slipping through the cracks last year at Walker Middle School where he met Fusco.
"I was getting low D's, sometimes C's, but I think I had an F too," said Nunez.
Fusco says Nunez was just off track so they spent an hour a day together, for months, Fusco teaching Nunez how to hear his teachers. In the end, he has helped not just with school, but also with life.
"He would doubt himself, he would raise his hand and I would come over and he would say, 'Am I doing this right?' And I would say, 'You have it!' And he would say, 'I was just testing you, just testing you Mr. Mike' and I was like alright," said Fusco.
This year they've both moved on to Oakridge High School and Nunez no longer needs that one-on-one tutoring.
"I had straight A's by my third semester in all my classes," said Nunez excitedly.
Nunez says he now wants to go to college and make his mom proud.
Click Here for more information on the City Year and how to bring the program to your child's school.
Copyright 2014 by ClickOrlando.com. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

subset: commoncrawl


text:
207 Blackburn Drive, Brantford – 4 bed, 2.5 bath home on tree lined lot
More Photos Specifications Price: 567,995 Beds: 4 Baths: 2.5 Square Feet: 2030 Lush, tree lined lot Located in Brantford 207 Blackburn Drive - Brantford Real EstateBetter than new! Welcome Home to #207 Blackburn Drive. This stunning single family home is located in desirable West Brantford....
Jordan Jeffries
17:21 31 Oct 17
We love working with Andrew and Kate! They are super pro and have what it takes to get the job done! Thanks for the hard work! Most definitely will be calling on them again when it comes time to buy or sell.
Josh Ticsay
17:18 31 Oct 17
Extremely knowledgeable, super professional, very easy to talk to! Would recommend to any of my friends and family!
Joyce Minten
01:14 26 Jul 17
From start to finish, Andrew, Kate and Jamie were an amazing team to work with in the sale of my home! They each brought their area of expertise to the table to provide a full package. They guided me through every step of the process and were consummate professionals offering their knowledge, skills and unique talents to ensure my home was well-presented and well-represented on the market. They were dedicated and worked hard to produce the best result. My home sold for substantially over asking in just a few days! I could not have been happier with the process or outcome! I would highly recommend this exemplary team for anyone selling or buying a home!
Daniel Opper
03:29 19 Jun 17
Amazing customer service. Positive, but genuine and honest feedback. Not only helped with purchase of home, but with helping us find contractors for different renovation jobs, as well as introducing us to the neighborhood. After closing, Kate continued to follow up to see how things were. Would definitely recommend.
David Prang
18:43 14 Jun 17
Sara and I had a wonderful experience working with the Andrew and Kate team. They took time to understand our needs, explained items clearly, had an up to date strategy that worked in this crazy environment, and were responsive to our questions. We would highly recommend them for your next real estate transaction! Plus, a super cool gift at our closing! Thanks Andy and Kate!


text:
Gmail Gets Drag-and-Drop Attachments
Clicking all those buttons on your e-mail is such a drag. Luckily, Gmail has come up with a way to attach files in one step: Users in Google Chrome or Mozilla Firefox 3.6 can now drag and drop their files into Gmail directly from a folder on their computer.
"I used to have to click 'Attach a file,' find the photos, click them, etc. Starting today, if I'm using Google Chrome or Mozilla Firefox 3.6, I can just drag and drop the files to attach them--easy as pie," Adam de Boor, a Google software engineer, wrote in a blog post.
Google also launched a feature the provides tighter integration between Gmail and Google Calendar. When you compose an e-mail, there is now an "Insert: Invitation" link under the subject line. Clicking on that will pop up a window that displays your scheduled, as well as the schedule of the person you're e-mailing (if you have permission to see it).


text: The third wife of Bolingbrook, Ill., police sergeant Drew Peterson, Savio, 40, was discovered by neighbors in her home in an empty bathtub with a 1-inch gash on the back of her scalp in 2004. Savio and Peterson were divorced, but the details of the divorce settlement were weeks away from being finalized when she died. Her death originally was ruled an accidental drowning, but authorities later said it was a homicide staged to look like an accident. Peterson is now in jail on murder charges in the death, and has pleaded not guilty.


text:
The bell tones that indicate class breaks over the loudspeakers at Corte Madera Middle School in Portola Valley are different for the 2011-12 school year, as annoyed residents, through a couple of representatives, attested to at the Sept. 14 Town Council meeting.
The tones are of at least two types, are more frequent than usual, are loud enough to be heard beyond the campus and are disrupting the normal daytime peace of nearby neighborhoods, resident Danna Breen told the council.
The Portola Valley School District essentially concurs and is taking steps, district Superintendent Tim Hanretty told the Almanac.
The council listened to Ms. Breen but did not comment. Under the rules for parliamentary procedure, comments would have been inappropriate since the matter was not on the formal agenda for the evening.
"Everybody is really shaken about this. It's like the Sound of Music. Every class has a sound to which they jump," she said. "I'm telling you it's wildly intrusive."
"Every 15 minutes the bell is ringing twice," she added. "I am speaking on behalf of a lot of people. We will drag the troops in (to a council meeting) if it doesn't stop soon."
"Bell is not the right word," Jon Silver, a resident and a former mayor, added. "It's more like an ersatz train whistle. It is odd. It is frequent."
"We think it very raucous and needlessly loud," Hartha Hanerfeld, a neighbor of Ms. Breen's, said in a telephone interview. The bells are audible on remote hikes on Coal Mine Ridge and Windy Hill, she said.
"It sounds like a siren," said Tan Oak Drive resident Mary desJardins in a phone interview. "It's auditorially disruptive. I can hear it all day long. What they have right now is like bad noise pollution. It's a very unpleasant sound."
Robert Pierce, also of Tan Oak Drive, called the bell "an annoying horn or klaxon."
Mr. Silver had recommended, since public school districts are not constrained by zoning laws, that the council try gentle diplomacy but it appears that may not be necessary.
Mr. Hanretty acknowledged the problem in forwarding to the Almanac a recent email message to Town Manager Angie Howard.
The school is perched alone on a hill in a relatively densely populated area of Portola Valley. The school bells were reprogrammed this year to accommodate a new three-part class schedule for fourth- and fifth-graders, for sixth-graders, and for seventh- and eighth-graders, Mr. Hanretty wrote.
"I concur that the tone that was added to accommodate the third (new) bell schedule is quite shrill," he wrote. "We are working to replace it with something less shrill."
Another problem: the speakers outside the classrooms are supposed to be heard just four times a day: when classes start, at the ends of recess and lunch, and at the end of the day. "At present, it appears that the bells are ringing inside and outside throughout the day," Mr. Hanretty wrote.
"Like so many things these days, we are not able to program the bell system ourselves," Mr. Hanretty continued. "We rely, as so do most schools in this area, on an outside firm to handle changes and adjustments to the system."
The Bay Area has just one firm that services this type of bell system and Portola Valley is in the queue, Mr. Hanretty wrote. The administration is also looking into reducing by half the duration of the ringing.


text:
The information in this Release Notes file pertains to Novell® PlateSpin® Recon 3.6.1.
For instructions on downloading and upgrading to PlateSpin Recon 3.6.1, see "Upgrading PlateSpin Recon" in the Novell PlateSpin Recon 3.6 Getting Started Guide.
For administrative tasks, see the Novell PlateSpin Recon 3.6 User Guide.
PlateSpin Recon 3.6.1 includes the following new features:
Support for New Platforms: This release enhances the existing comprehensive platform support with the addition of support for VMware* vCenter Server 4, VMware ESX 4.0, and VMware ESXi 4.
Support for New Processor: This release provides support for inventory and data collection for the Intel* Xeon* processors based on the Nehalem architecture processor.
The following issues that were discovered in the original shipping version of PlateSpin Recon 3.6 have been resolved in this release:
495106: PlateSpin Recon Inventory of VC2.5 fails with the message No output returned from the script execution.
510350: PlateSpin Recon 3.6 Inventory hangs the servers.
515062: ESX edition for ESX 4i is displayed incorrectly. In thetab of the ESX machine Properties page, the edition of the inventoried ESX 4i machine is incorrectly displayed as 3i instead of 4i.
Novell, Inc. makes no representations or warranties with respect to the contents or use of this documentation, and specifically disclaims any express or implied warranties of merchantability or fitness for any particular purpose. Further, Novell, Inc. reserves the right to revise this publication and to make changes to its content, at any time, without obligation to notify any person or entity of such revisions or changes.
Further, Novell, Inc. makes no representations or warranties with respect to any software, and specifically disclaims any express or implied warranties of merchantability or fitness for any particular purpose. Further, Novell, Inc. reserves the right to make changes to any and all parts of Novell software, at any time, without any obligation to notify any person or entity of such changes.
Any products or technical information provided under this Agreement may be subject to U.S. export controls and the trade laws of other countries. You agree to comply with all export control regulations and to obtain any required licenses or classification to export, re-export, or import deliverables. You agree not to export or re-export to entities on the current U.S. export exclusion lists or to any embargoed or terrorist countries as specified in the U.S. export laws. You agree to not use deliverables for prohibited nuclear, missile, or chemical biological weaponry end uses. Please refer to the Novell International Trade Services Web page for more information on exporting Novell software. Novell assumes no responsibility for your failure to obtain any necessary export approvals.
Copyright © 2009 Novell, Inc. All rights reserved. No part of this publication may be reproduced, photocopied, stored on a retrieval system, or transmitted without the express written consent of the publisher.
Novell, Inc. has intellectual property rights relating to technology embodied in the product that is described in this document. In particular, and without limitation, these intellectual property rights may include one or more of the U.S. patents listed on the Novell Legal Patents Web page and one or more additional patents or pending patent applications in the U.S. and in other countries.
For Novell trademarks, see the Novell Trademark and Service Mark list.
All third-party trademarks are the property of their respective owners.


text:
Honors & Awards
Nebraska Scholar-Athlete Honor Roll (Fall 2013)
2013 (Freshman)
Martinez redshirted his first season at Nebraska.
Before Nebraska (Laguna Beach)
Drake Martinez joins the class after starring as a versatile two-way performer at Laguna Beach High School in California. The younger brother of Nebraska senior quarterback Taylor Martinez, Drake is one of three Californians in the Huskers' 2013 class, joining offensive standouts Johnny Stanton and Terrell Newby. During his senior season in 2012, Martinez rushed for 1,613 yards and 23 touchdowns, while averaging 9.4 yards per carry from his running back position. The 6-2, 200-pound Martinez counted a 95-yard touchdown run among his many rushing highlights. Martinez also caught six passes for 122 yards, with each of those catches resulting in a touchdown. On defense, he made 130 tackles and had four interceptions, returning those picks for 154 yards, including two touchdowns. Martinez also averaged 49.6 yards on kickoff returns and 57.0 yards on two punt returns. His play helped Coach Michael Churchill's team to an 11-1-1 record, an Orange Coast League title and a trip to the CIF-SS semifinals for a second straight year. Martinez was named the MVP of the Orange Coast League and was also named to the Orange County Register's All-County team. Martinez posted equally impressive numbers during his junior season, helping his team to a 10-3 record. He rushed for 1,889 yards and 27 touchdowns, while catching 12 passes for 285 yards and two touchdowns. Defensively, he added five interceptions, including a 62-yard return for a score. Martinez also saw varsity action during his sophomore season in 2010. Martinez is ranked among the top 70 safety prospects in the nation by Fox Sports.com. He is also ranked as one of the top 100 outside linebacker prospects in the country by 247 Sports, who also lists him among the top 130 players in California. Martinez also visited Michigan State, and also had offers from Vanderbilt and San Diego State.
Drake Martinez was born on Feb. 11, 1994, and is the son of Casey and Epifania Martinez.


text: I'm moving to Austin and the pickings appear to be slim for pit bull friendly housing. I've been told by several apt managers and apt locators that no apt in Austin accept pit bulls (or the other four aggressive breeds as listed by the AKC). However, I was contacted by Pat Faith, who has two pit bulls and lives in Austin. Pat lives at the Riata (http://www.riata.com) in NW Austin. Rent is ~$700/month and deposit is $400/pet. City transport is available to downtown Austin and the UT campus. Pat has requested that if anyone pursues a lease at the Riata to please tell the management that you were referred there by Pat. Pat offered to show me around the complex so if anyone else is interested let me know and I can pass on Pat's email address.


text:
HANG TIME HEADQUARTERS — If you've spent any time in the past two seasons contemplating the working dynamic between Heat stars LeBron James and Dwyane Wade, you're like the rest of us. You have your own theory about how two superstar teammates might co-exist, but you're not certain exactly how that dynamic breaks down from the inside.
Well, we're going to get as close to the middle as we can on Episode 75 of the Hang Time Podcast, breaking down all things Heat and the yin and yang relationship between the team's two biggest stars with Michael Wallace of ESPN.com and the Heat Index, who has as good a handle on that delicate relationship as anyone in the business.
We also check on the status of the New Orleans Hornets and their new owner, Saints owner Tom Benson, with longtime New Orleans Times-Picayune sportswriter Jimmy Smith (a cousin on the Cajun side of the family). Benson promises a championship contender in both the NBA and NFL for fans in the Crescent City. He also mentioned something about a name change from the Hornets to …
Check out all of that and more on Episode 75 of the Hang Time Podcast with Michael Wallace of ESPN.com and Jimmy Smith of the Time-Picayune.
As always, we welcome your feedback. You can follow the entire crew, including the Hang Time Podcast, co-hosts Lang Whitaker of SLAM Magazine and Sekou Smith of NBA.com, as well as our superproducer Micah Hart of NBA.com's All Ball Blog and the best engineer in the business, Jarrell "I Heart Peyton Manning" Wall.
– To download the podcast, click here. To subscribe via iTunes, click here, or get the xml feed if you want to subscribe some other, less iTunes-y way.


text:
I want to compile mysql-workbench but run into memory issues. My laptop has 2 GB of RAM. 64 GB SSD with one ext4 partition. I created a 2 GB swapfile on /.
This is df -lh
rootfs 59G 12G 45G 21% /
dev 959M 0 959M 0% /dev
run 970M 636K 969M 1% /run
/dev/sda1 59G 12G 45G 21% /
tmpfs 970M 628K 969M 1% /dev/shm
tmpfs 970M 0 970M 0% /sys/fs/cgroup
tmpfs 970M 16K 970M 1% /tmp
RAM keeps filling up from 500 MB to 1.1 GB then falls back to 500 MB. When reaching 1.2 GB it swaps some MB into the swapfile. Swappiness is at 30. That goes one for over a hour untill the build fails with some out of memory messages.
I looked into df -lh again and saw that /tmp was maxed out at 100%.
This is /etc/fstab:
# /etc/fstab: static file system information
# <file system> <dir> <type> <options> <dump> <pass>
tmpfs /tmp tmpfs nodev,nosuid 0 0
/swapfile none swap defaults 0 0
# UUID=2985462a-ac9c-48de-8bbf-0bbb83a4b4f3
/dev/sda1 / ext4 rw,relatime,data=ordered 0 1
I read the wiki that /tmp can be increased to more than 50% of physical memory with the size option but I'm not sure if that is a good idea.
Anyone has some ideas that would help me out?
Last edited by blackout23 (2013-01-17 20:59:05)
Are you using packer or somesuch? packer by default uses /tmp for building packages. If you compile outside of /tmp, files used while compiling won't be forcefully kept in your memory.
I simply let the PKGBUILD do it's thing. Compiling it via AUR. Really not sure what tools and parameters it uses. I did not change anything in that regard on my Arch system.
Last edited by blackout23 (2013-01-16 21:10:45)
Maybe you have BUILDDIR set to /tmp in makepkg.conf?
Builddir is actually commented out with # in /etc/makepkg.conf and refers to /tmp/makepkg
Would changing it to my homedirectory solve the problem?
If it's commented out, building should be done in the directory PKGBUILD is in. You could run makepkg and see what's growing in /tmp with "du -hs /tmp*". If you can't move it out of /tmp, then you could (temporarily) make /tmp use the disk, not RAM - if you're not using systemd, comment out /tmp in fstab and reboot; if you're using systemd, you'd probably (additionally?) need to disable the unit mounting /tmp as tmpfs or somesuch.
By default, /tmp defaults to half your RAM if mounted in tmpfs. You can increase it to possibly 1.5Gb using the size=1536M mount option although you may still get OOM errors if your system uses more than the remaining if the compile fillls it up. You can also change the compile path to your ~
2 G might not be enough. As others have pointed out, tmp is 1/2 physical by default. Do you know how large the package you want to build is on disk with source and tmp files from make, etc? I'm guess >1 G. If you want to compile in RAM, consider adding more to the machine. If you cannot or will not, compile on disk.
CPU-optimized Linux-ck packages @ Repo-ck • AUR packages • Zsh and other configs
Yes I'll just have to compile it on the disk. Obviously commenting something out in /etc/fstab out is not enought I'd also have to "sudo systemctl mask tmp.mount". Did not have time for this as of yet. Thanks for all your contribution!
2 GB is the RAM limit on my laptop motherboard. For 99,9% of my other tasks the laptop is more than adequat and fast enough.
Last edited by blackout23 (2013-01-17 20:58:05)


text: Add new comment Your name Subject Comment About text formats CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Math question 7 + 6 = Solve this simple math problem and enter the result. E.g. for 1+3, enter 4. सेव Preview


text:
Shannon Lee, the only surviving child of Bruce Lee, grew up in Hong Kong and Los Angeles. Her father, a big-screen martial-arts legend, would have been 71 this year. His daughter heads his corporate legacy as CEO of Bruce Lee Enterprises and president of the board of directors for the Bruce Lee Foundation. Based in Los Angeles, the 42-year-old actress/singer/entrepreneur may be seen next in "I Am Bruce Lee," a feature-length documentary that soon will air on Spike TV.
Q: What is your favorite vacation destination?
A: I love going to Kauai. I love the tropical weather, the lush landscapes and seascapes. There's a particular ease that takes over your body when you wrap yourself in those warm trade winds. I also have dear friends there, so it's like family — family you actually like hanging out with. It used to be that you had to stop in Hawaii when traveling from the West Coast to Asia, and we would stop there often, so my relationship with Hawaii is long and enduring. I also love the hustle and bustle of Hong Kong. I stay with friends there, and we eat and shop till we drop.
Q: Where are your favorite weekend getaways?
A: Weekend getaways are too few and far between. Santa Barbara is great. Ojai (in California) is a lesson in relaxation. Vegas is a lesson in sleep deprivation and sensory overload, but very fun. Palm Springs is nice too.
Q: What are your favorite hotels?
A: Ojai Valley Inn and Spa (ojairesort.com) is wonderful. There's a little something for everyone there in the way of recreation and relaxation. I recently stayed at the Ritz-Carlton (ritzcarlton.com) in Tokyo. What a beautiful view of the city from the rooms! I have fond memories of the Island Shangri-La (www.shangri-la.com/en/property/hongkong/islandshangrila) in Hong Kong as well. The nighttime view of the harbor is stunning, almost mesmerizing.
Q: What are your favorite restaurants?
A: Well, Arirang Korean Restaurant (arirang.com.hk/eng/index.aspx) in Hong Kong is a sentimental favorite. I love Korean barbecue, and this place is just full of great memories with family and friends. We eat there almost every time I'm in Hong Kong. When I was doing concerts in Hong Kong in 2004, we had it brought into the Hong Kong Coliseum some nights before the show. Also, NBC Seafood Restaurant (nbcrestaurant.com) in Monterey Park, Calif., has great dim sum — authentic, great variety, delicious. You can really scratch your dim sum itch there. Lastly let me say this: New Orleans — from my old sentimental favorite of turtle soup and bread pudding souffle at Commander's Palace (commanderspalace.com) to burgers and grilled pecan pie a la mode at Camellia Grill (camelliagrill.net/home.htm) to hot 3 a.m. beignets at Cafe Du Monde (cafedumonde.com) and on and on. I love it!
Q: What are your favorite cities?
A: Any surprise that I would say Hong Kong? I love Hong Kong. It's my home away from home. New Orleans. I lived there for six years and fantasize repeatedly about spending more time there. I've had wonderful adventures and experiences in Prague, Amsterdam and Hakone (in Japan). But if we are talking about places I return to spend time, it would be Hong Kong, New Orleans, New York City, Kalaheo, Kauai and Los Angeles.
For more from the reporter, visit jaehakim.com.


text:
It's a coincidence, but not a surprise, that both productions of Othello I've seen recently are set on military bases in today's Middle East. The garrison in Shakespeare's tragedy isn't that far from an outpost in Kandahar. The same rules of life in the battle zone apply: the peremptory chain of command, the hair-trigger emotions stirred by dangerous deployment, and most important, the implicit trust in the comrades-in-arms your life depends on.
Both productions evoked that atmosphere, along with the camouflage fatigues and semi-automatic sidearms of today's soldier, but also diverged sharply. Where the Royal National Theatre's staging, beamed from London in its NT Live-to-cinema series, boasted 20 performers, an expansive stage and a budget to match, the local offering by Real Live Theatre was performed in a bare room under fluorescent lights with a cast of eight.
That said, both were examples of Shakespeare at his riveting best, giving a spine-tingling urgency to the 400-year-old tale of the black general in a white world who's led, by loving "not wisely but too well," into jealousy and murder.
Real Live Theatre is a brand-new ensemble that brings a thrilling immediacy and creative savvy to the stage. Founded by alums of Serious Play's training program, its focus is on the actors' intense physical presence. In Ellen Morbyrne's production at Gateway City Arts in Holyoke, the performers sat among the audience on folding chairs, entering into the bare playing space on cue but never really out of the action.
In this present-day setting, Othello was not a "Moor," but a Puerto Rican, affectingly embodied by Arnaldo Andre Rivera, who had a couple of exchanges in Spanish with his lieutenant Cassio (Mike Pray). Thanks to some plausible cross-gender casting, half the cast was female, and included feisty performances by Emma Jimerson as Othello's wife Desdemona and Monica Giordano as Iago's wife Emilia. For me, the defining performance was Dan Morbyrne's as the "demi-devil" who ensnares the trusting Othello. His Iago was a playful, loose-limbed fellow whose lying tongue spoke in hip-hop rhythms—a brilliant incarnation of the modern warrior.
In the National Theatre production, which has repeat screenings at Amherst Cinema this weekend and later this month, Rory Kinnear's Iago is the same breed—street-bred and sassy, this time with a Cockney accent. He's the perfect foil for Adrian Lester's poised, charismatic Othello, and it's breathtaking to see Iago's game of lies and innuendo lead the proud man to destruction.
Director Nicholas Hytner says "the army is absolutely central" to his concept, and designer Vicki Mortimer's set of uprearing cement barricades and klieg lights not only sets that tone but is also constantly shifting to reveal ever-more-confined spaces, as unstable as the plot's plunging swings of fortune.
In a cast as strong and supple as you would expect in Britain's premier playhouse, there's one jarring note. In an apparent attempt to present Othello's blonde bride Desdemona as more spirited and independent than she's often portrayed, Olivia Vinall, dressed incongruously in faded blue jeans, comes off more like a frisky adolescent than a general's wife.
Shakespeare is a constant presence in this NT Live season. Next week is Macbeth with Kenneth Branagh as the bloody Scot, followed by an encore showing of 2010's Hamlet with Rory Kinnear, and then Tom Hiddleston as Coriolanus in the new year. Contact amherstcinema.org for info and schedules.•
Contact Chris Rohmann at email@example.com.


text:
Physical Sciences
Research Highlights
July 2005
Barrier-Free Intermolecular Proton Transfer - A Step towards Understanding of Mutagenic Effects of Low-Energy Electrons
Thymine, lower left, bonds to glycine in DNA
Low-energy electrons (with energy below 20 eV), such as those released during radiolysis of water, are known to induce single- and double-strand breaks in DNA. A newly discovered phenomenon - barrier-free proton transfer (BFPT) induced by an excess electron - might explain how the breaks occur. In parallel theoretical calculations and photoelectron spectroscopic experiments, we studied anionic binary complexes, made up of nucleic acid bases (NB) and various weak acids (HA), generally represented as [(NB)(HA)]-. Attachment of an excess electron triggers a barrier-free, intermolecular proton transfer from many acids to the base with the new product forms being a neutral hydrogenated base radical, (NBH.) and the deprotonated acid, A-.
(NB)(HA) + e- → (NBH·) + (A-)
An example of this is shown in the figure. Thymine, lower left, bonds to glycine in DNA. An electron attaches to the thymine, giving it a negative charge. A proton moves from the glycine moiety to the thymine in a barrier free proton transfer, giving the glycine a negative charge.
The driving force for proton transfer is the stabilization of the excess electron onto a π* orbital of the base. Thus, one may envision the process as one in which the excess electron first attaches itself to the nucleic acid base moiety of the dimer, forming a very strongly basic anion, which then extracts a proton from the HA portion of the dimer to yield the complex, (NBH·)(A-). The radical, NBH·, may then initiate further transformations, leading to the rupture of the sugar-phosphate bond. We computed the barrier for NBH radical-induced, sugar-phosphate rupture to be less than 7 kcal/mol.


text:
KNIGHT firstname.lastname@example.com_current.manitoulin_expositor 2001-09-12 published
Thomas Brian PORTER
In loving memory Thomas Brian PORTER, November 9, 1937-September 2, 2001.
Tom PORTER, a resident of Gore Bay, died at the Manitoulin Health Centre, Little Current, on Sunday, September 2, 2001, at the age of 63 years. He was born in Sudbury, son of the late Thomas Reginald and Annie Margaret {BUCHANAN} PORTER.
Tommy had taught school from 1969-1979, in Gore Bay, Capreol and lastly in West Bay at Manitoulin Secondary School. In his earlier years, he enjoyed figure skating. Tom also enjoyed reading and arts and entertainment. He will be sadly missed by his Friends and loving family.
Loving brother of Marianne KNIGHT of Toronto, Margaret PORTER of Toronto, Rob Roy PORTER and his wife Linda of Sault Ste. Marie, and sister-in-law Eldene and her husband Buck LONGHURST of Sault Ste. Marie. Also survived by several nieces and nephews. Predeceased by brother Godfrey.
Tom's request was that there was to be no visitation or funeral service. Cremation will take place followed by burial of ashes. A memorial service will take place on Saturday, August 31, 2002. Arrangements entrusted to Culgin Funeral Home, Gore Bay.
K... Names KN... Names KNI... Names Welcome Home
KNIGHT - All Categories in OGSPI


text:
Author Notes: This is not a quick dish by any means but the resulting green pasta is gorgeous, really tasty and totally worth the time. You could use the pasta recipe alone for ravioli or fettucini. I adapted what was a lasagne dish from A Platter of Figs into a rolled pasta topped with a tomato sauce and mozzarella cheese. This is a great way to get in your veggies, especially if you aren't a fan of some of the more bitter greens. This recipe uses a mix of baby spinach, chard and curly mustard but it would work well with kale, rapini, etc. Prepared casserole should be refrigerated for a day before cooking, so be sure to plan ahead. Great for when you have a lot of time one day but know you will be rushed to make dinner the next. You can also save some time by using a jarred tomato sauce rather than make your own. - epicker —epicker
Food52 Review: I picked this recipe because it includes all my favorite ingredients and I wanted to work on my pasta-making skills. The pasta has a great color, taste and texture even though it was likely rolled a little thicker than epicker's. The ricotta, mixed with the wilted garlic greens and lemon zest, was robust with flavor and yet light; I will be hard-pressed to not add lemon zest to all my ricotta! We ate the cannelloni for two meals over the weekend. My only regret is that I didn't double the recipe and freeze some. This is a very good dish! - LLStone —LLStone
Makes: one 9x13 casserole dish
cups mixed greens (baby spinach and chard), chopped
large eggs
teaspoon kosher salt
tablespoons olive oil
cups all purpose flour, plus more sprinkling
tablespoons olive oil (divided)
garlic cloves, minced (divided)
pinches red pepper flakes
pounds greens, rinsed well and roughly chopped (e.g., mix of baby spinach, chard, curly mustard)
ounces ricotta cheese
grated zest of 1/2 lemon
salt and pepper, to taste
28 ounce can whole, peeled tomatoes
small handful basil, torn
1 1/2
cups mozzarella cheese, shredded
- For the pasta, combine greens, eggs, salt and olive oil in food processor fitted with metal blade. Puree until smooth.
- Transfer puree into a large bowl, stir in 2 cups flour. Knead in up to 1 more cup of flour until dough is no longer sticky. It may look dry, that is okay. Turn out onto counter sprinkled with a bit of flour and continue kneading until it comes together in a ball. Cover in plastic wrap and set aside at room temperature while you prepare the filling and sauce.
- In a large saucepan, heat 3 tablespoons of olive oil. Add 4 tablespoons garlic and cook for a few minutes but do not let it brown. Add red pepper flakes and then the greens. Stir and let greens wilt for a few minutes. Season with salt and pepper then transfer to a colander to drain and cool.
- In a medium bowl, combine ricotta cheese with lemon zest, salt and pepper. Stir to combine and set aside.
- In a medium saucepan, heat remaining tablespoon of olive oil. Add remaining tablespoon of minced garlic and chopped onion. Cook for a few minutes until onion begins to soften. Add tomatoes (do not add liquid) and crush with a fork. Let simmer on low heat while you roll out the pasta.
- Fill a large saucepan with water and bring to a boil. Fill a bowl with ice water and set next to the stove. Divide pasta dough into four sections and flatten each one slightly. Working with one section at a time, run pasta through machine at the lowest setting. Fold in half and repeat until pasta forms a rectangle the width of the pasta maker and about 6-7 inches long. Don't fret if it is crumbly or has holes at first, this will remedy itself. Next, run sheet of pasta through machine once at each number, working from 2 to about 5 or 6. You will have a very thin and very long sheet of pasta. Set aside (uncovered) on a well floured counter and repeat with remaining sections.
- When you have four long sheets of pasta, cut each sheet into rectangles roughly 8 inches long. You should have about 16-20 rectangles. Working with 2 at a time, drop into pot of boiling water for 45 seconds to 1 minute. Remove with a spatula and drop into bowl of ice water to stop the cooking. Then place each sheet on kitchen towels to dry. Repeat until all pasta sheets are partially cooked, adding more ice to the bowl of ice water as necessary. Try to keep cooked sheets from touching each other, as they will stick. Don't worry about any small tears.
- Spray a 9x13 casserole dish with oil or cooking spray. Squeeze out any remaining liquid from the cooled greens, chop finely and add to ricotta mixture. Remove tomato sauce from heat. Add torn basil and then puree with an immersion blender until it is as smooth or chunky as you like.
- Working with one pasta sheet at a time, place on a cutting board with the short side facing you. Spread a scant tablespoon of filling along the side closest to you and roll away from you to form a cigar shape. Place in casserole dish parallel to the short side. Repeat with all pasta sheets - you will use about 16-18 sheets forming 2 layers.
- This recipe is a Community Pick!
- This recipe was entered in the contest for Your Best Greens
More Great Recipes:
Italian|Vegetable|Cheese|Make Ahead|Vegetarian|Side|Entree


text:
Mills Woman Admits Charity Theft [AUDIO]
A parcel of state land near Burlington, used as an unauthorized dump site, was recently cleaned up at a cost of $147, 500. Amy Richards reports. A Mills woman is headed to jail after admitting to stealing from a charity. Kevin Koile has details. Click past jump to listen to Wyoming Radio News.


text:
January 24, 2012
This course is intended primarily for students majoring or minoring in computer science or information systems. It assumes CSC 270 as a prerequisite.
In CSC 270, you studied several different languages and paradigms of programming, from the perspective of a programmer using the language. In this course, we'll look "under the hood" at how a programming language works: how do compilers and interpreters represent a program's logical structure, how do they translate between a sequence of characters and that logical structure, how do they resolve variable and function names, how do they enforce data type rules, etc.
This is not quite a "compiler construction" course -- we won't go into great depth on the practicalities of scanning, parsing, code generation, symbol table implementation, optimization, and so on -- but we'll get a taste of those topics, and learn enough about the job of a compiler or an interpreter to understand why particular features of our favorite languages are the way they are. We'll explore different ways those features could work experimentally, by writing interpreters for different versions of a language and seeing how they work. If you do go on to take a compiler construction course, you'll have a very solid grounding in the relevant terminology and issues, and will only need to learn implementation techniques.
You'll also become acquainted with a number of powerful language features you may not have seen before: first-class functions, lazy evaluation, lexical vs. dynamic scope, and continuations. As a bonus, you'll see a very different, and more natural, way to write interactive Web applications.
We'll be using two textbooks. One, Sebesta's Concepts of Programming Languages, should be in the Bookstore (and in the Library, albeit probably an older edition). It's a "classic" programming-languages text, giving a lot of history, a fair amount of theory, and some code examples.
The other main textbook, Krishnamurthi's Programming Languages: Application and Interpretation, is available on the Web for free. This is a very hands-on book, taking the philosophy that you never really understand how a program works until you've implemented it yourself. Accordingly, it leads the reader through the implementation of a series of interpreters for programming languages with various features. The book is on the Web at www.cs.brown.edu/~sk/Publications/Books/ProgLangs/.
We'll also use some on-line sources, such as Learn You a Haskell for Great Good, which despite the name is an extremely readable introduction to the Haskell language.
We'll start by discussing the criteria for a "good" programming language. Of course, different languages are "good" for different purposes; for the purpose of writing interpreters, Racket seems to be especially good, so we'll do most of our programming assignments for the semester in Racket. For those of you who haven't done much Racket programming, or who haven't done it in over a year, we'll spend a few days reviewing Racket and learning some language features that will be particularly helpful in our projects.
The rest of the semester will be "hands-on", working through the implementation of a number of language features in the Krishnamurthi book.
For a detailed, class-by-class schedule of readings and topics, see
There will be about 8 homework assignments, each involving the implementation of some language features, and often with some reflective written questions as well. There will be a two-hour final exam on May 17, from 10:30 AM to 12:30 PM, and there will be a "class participation" component to the grade.
The final exam must be taken at the scheduled time, unless arranged in advance or prevented by a documented medical or family emergency. If you have three or more exams scheduled on the same date, or a religious holiday that conflicts with an exam or assignment due date, please notify me in writing within the first two weeks of the semester in order to receive due consideration. Exams not taken without one of the above excuses will be recorded with a grade of 0.
Every program must contain, in the first few lines, a comment indicating the name of the student(s) working on it and what the program is supposed to do. Programs not containing this information, clearly visible, will get a zero.
Every program must be adequately and accurately commented, as appropriate in the current language.
Programs are not abstract works of art, they are supposed to run and solve real problems. So if I get a program that doesn't compile or run, I will give it a zero, no matter how much time you put into it. Don't bother turning in a program you haven't tested yourself.
I recommend writing most of the programming assignments in teams of two students.
The Adelphi University Code of Ethics applies to this course; look it up on the Web at academics.adelphi.edu/policies/ethics.php .


text:
World Tour Plan was established in 2009 by a team of true professionals equipped with years of experiences and capacity in the tourism and hospitality industry. Emblazoned with our mission of being 'At its best for Travelers' we endeavor to make each one of your visits a truly special one. Our tour packages are designed in such a way that through them, you get the real taste and treat of true Bhutan.
We also provide special interest trips that acquaint visitors with even the minutest details of this wonderland called Bhutan. Our trips are led by a team of professional guides certified by the Tourism Council of Bhutan. These guides are well equipped with all the skills, attitude, aptitude and knowledge pre-requisite of a tour...Read more
Nestled in the Eastern Himalayas, Bhutan is one of the most popular travel destinations in the world, often known as the 'Last Shangri-la'. From the picturesque villages to the colorful monasteries perched on cliffs, to spotting endangered black necked cranes and to soaking in the sights of the mountains splashed with rhododendron blooms, it is packed with cultural and natural treasures. Bhutan's natural beauty and spectacular charm never fails to reward the inquisitive.


text:
Patra Photos
342 Photos by Greeka and our members
Discover the amazing Patra Photos, uploaded by Greeka and our members. We have chosen the best pictures of Patra from our database and uploaded them in this section.
Members of Greeka.com have also uploaded their photos of Patra. Some photos are professional, others are amateurish, but they all show their love for this special place in Greece. If you have some Patra Photos, feel welcome to upload them in our website. Sign up with Greeka and start sharing your experiences from Patra. If you already have an account in Greeka, just log in.
To get a better view of the island, apart from photos, check our section with Videos.
Photos of members by location and sightseeings
Photos of Patra by Greeka.com


text:
Loyola's Psy.D. program employs a unique, service-oriented educational method and trains doctoral students to become innovators and leaders capable of meeting the evolving demands of mental health service providers. The program is accredited by the American Psychological Association, adheres to the scholar-practitioner model of education, emphasizing the integration of a comprehensive knowledge base, appropriate attitudes and clinical skills.
The first program of its kind in Maryland, this full-time, five-year course of study (four years for those who hold a qualifying master's degree) leads to licensure in any state. All students must submit and pass a background check prior to admission. Psy.D. students take four/five courses per semester and devote approximately 10-16 hours per week to clinical training. Other program requirements include both written and oral comprehensive examinations and a dissertation.
Applicants with a master's degree and appropriate course work will be considered for advanced standing (admission to the second year of the curriculum). The first through fourth years of course work and clinical experience are completed at Loyola's campus in Baltimore and at area field placement sites. The fifth year is a full-time clinical internship, which may or may not be located in the Baltimore area.
Mary Jo Coiro, Ph.D.
Traci Martino, M.S., Director, Program Operations
*Questions related to the program's accredited status should be directed to the Commission on Accreditation:
Office of Program Consultation and Accreditation
American Psychological Association
750 1st Street, NE
Washington, DC 20002
Phone: (202) 336-5979
Email: email@example.com
Web: http://www.apa.org/ed/accreditation
From the moment Aileen first learned about the definition of the word "psychology," she knew that she wanted to work in the field


text:
BOSTON, Mass. - For the first time in the history of University of Massachusetts Boston soccer both the men's and women's soccer programs will be competing in a postseason tournament in the same year. Both teams not only earned a bid to the ECAC New England Region tournament, but they were also selected as the fourth-seed. Women's Soccer will host #5 Endicott College on Wednesday at 2 p.m., while men's soccer will travel to #5 Norwich University for a 1 p.m. match, which will also be played on Wednesday.
On the men's soccer side, the meeting between the Beacons (11-5-0) and the Cadets of Norwich University (11-9-0) will only be the second-ever in the history of the two clubs. The last time the two met was in 2001 as part of the Albertus Magnus Fall Classic in New Haven, Connecticut. Norwich defeated UMass by the final score of 4-0 on the second day of that tournament.
The tournament appearance will be the first of any kind for the Beacons since 2006. This season, the Beacons produced their first 11 win record since their '06 campaign. Led by sophomore Stefanos Galouzis (Watertown, Mass.), men's soccer has scored a combined 43 goals this season, while only surrendering 15. Junior goalkeeper Brycen Dowd (Mansfield, Mass.) has posted a single-season best seven shutouts, which includes two over Little East Conference opponents Western Connecticut State University (4-0) and the University of Southern Maine (3-0). Galouzis has had another strong year for the Beacons, as he currently leads the team in all offensive categories. On the year he has found the back of the net 12 times, while also dishing out seven assists for a combined 31 points (1st in the LEC).
2011 ECAC New England Men's Soccer Tournament
First Round - Wednesday, November 9
No. 8 Southern Vermont (12-5-1) at No. 1 Brandeis (12-5-1), 7:00 p.m.
No. 7 Endicott (8-8-3) at No. 2 Albertus Magnus, 1:30 p.m.
No. 6 Worcester State (8-8-2) at No. 3 Castleton (12-6-2), 6:00 p.m.
No. 4 UMass Boston (11-5-0) at No. 5 Norwich (11-9-0), 2:00 p.m.
Semifinals- Saturday, November 12 (at highest remaining seed)
No. 1/No. 8 winner vs. No. 4/No. 5 winner, TBD
No. 2/No. 7 winner vs. No. 3/No. 6 winner, TBD
Championship- Sunday, November 13 (at highest remaining seed)
Two Semifinal Winners, TBD
For the women's team, this will mark their third straight ECAC tournament appearance, and second time that they have faced Endicott College (12-7-0). Last season, the two teams met in the semi-final round, with Endicott earning a 3-0 victory.
UMass (13-6-2) will look to bounce-back from their tough penalty-kick loss to Keene State College in the Little East Conference tournament semi-finals. The Owls, who were defeated by Eastern Connecticut State University also in penalty kicks, earned the number two-seed in this year's ECAC tournament.
Playing a major part in the Beacons 13-win season has been freshman standout Krista Ledin (Bridgewater, Mass.). A possible LEC Rookie of the Year honoree, Ledin has been sensational for UMass with her conference leading 20 goals -- tied the single-season program record -- and 44 points. Alongside her is senior Kristin Mulry (Holbrook, Mass.), who along with her five other classmates will look to end their careers at UMass hoisting the program's first-ever postseason tournament championship.
Just like their male counterparts, the women's side will feature a standout goalkeeper in freshman Dani Perkins (Murrieta, Calif.). In her rookie season, Perkins has allowed a mere 14 goals against, and currently holds the single-season and all-time career shutout record with 10. Her 0.67 goals against average leads the Little East Conference going into this year's tournament.
If both teams are successful on Wednesday then they will advanced to the semi-final round which will be played on Saturday. The highest remaining seed left in each tournament, following the quarterfinal round will host both the semi-finals and the championship, which is scheduled to be played on Sunday.
2011 ECAC New England Women's Soccer Tournament
Quarterfinal Round - Wednesday, November 9
No. 8 Univ. of New England (12-2-3) at No. 1 Worcester State (13-5-1), TBD
No. 7 Norwich University (11-4-3) at No. 2 Keene State (13-7-2), 6:30 p.m.
No. 6 St. Joseph's College (CT) (12-6-2) at No. 3 Salve Regina (13-6-1), 1:00 p.m.
No. 5 Endicott College (12-7-0) at No. 4 UMass Boston (13-6-2), 2:00 p.m.
Semifinals- Saturday, November 12 at highest remaining seed after quarterfinal games
No. 1/No. 8 winner vs. No. 4/No. 5 winner, TBD
No. 2/No. 7 winner vs. No. 3/No. 6 winner, TBD
Championship - Sunday, November 13 at highest remaining seed after quarterfinal games
Two Semifinal Winners, TBD


text:
In the big scheme of things, The Revivalists are still a relatively new band. They've been together 7 years, which in dog years is only 1, but I'll be damned if they don't have as many die-hard, cult-status fans as The Rolling Stones. The venue was packed even before the opener, and the minute These Mad Dogs of Glory had cleared the stage after their spectacular performance, the air was buzzing with feverish anticipation.
I, a virgin to seeing The Revivalists live, was in the minority. All around me people were trading stories about how far they drove to see the band, how many towns they've followed them to. Surprisingly, it didn't sound like the overwhelming majority of people had that drawling, southern twang to their accent, which means that while these guys are still adored by their hometown, the music will make road-tripping followers of us all—regardless of your address. Luckily, I had a chance to sit down with them before the show, so I had already formed a crush on the six of them. Before I met them, I had a crush on their music, their unique sound and soulful, mind-bending lyrics are impossible to deny, but, as Rob put it in the interview: "we get more explorational during live shows." I can testify to that.
Have you ever heard the saying in Austin: "If you don't like the weather, wait five minutes?" That sentiment was forefront during the performance. You're not a huge fan of funk? The next song will be soul. Rock is too harsh for you? Then you'll love this track that's reminiscent of R&B.
And here's the killer part—they nail every genre. When I spoke to them, they were very clear about it being a point of pride for the band that they don't fit a specific genre. What they failed to mention is that many bands don't 'fit a specific genre', but they alone sound like professionals in every single one.
Although it's hard to make out David's voice over the crowd belting out every single verse, it's made easier due to the fact that he rarely stays on the stage. For the better part of the show, he's standing on benches, amps, speakers, or on the floor in the middle of it all, inciting dance riots. Girls are swooning, guys are swooning, everyone is fallen victim, no one is safe. If funktastic bass lines, kickass saxophone solos, and rock n' roll vibes are your thing, this is a can't-miss show.
The energy is inexplicable, it's something you just have to witness. They were right, there is something (dare I say it?) voodoo about their live perfomance. New Orleans has rubbed off on them for sure. Like Andrew said: "it's all about just having a good time, at the end of the day. I mean, the songs are serious and are about things we've gone through, and the songs individually have messages, but in terms of when we take the stage, live, more than anything else I want people to just leave and be like 'That was a good time.'" So while there's certainly nothing wrong with their studio album, my advice is to buy yourself a little Mardi Gras present this year: City of Sound with the added live tracks. It's magic.


text:
This website uses cookies. By clicking on 'I accept', closing this message and/or continuing making use of this website you grant this website permission to store cookies on your computer. You can read our cookie policy and privacy terms by clicking this link.
Contact us
1 702 637 0071 (Answering Service).
[email protected] Non-domains sales related emails.
Elite Domains, 848 North Rainbow Blvd. #1859, Las Vegas, Nevada 89107, USA.
Copyright © EliteDoms.com 2004 - 2019. All rights reserved.


text:
A group of New York Jets season ticket holders are suing the organization for no longer requiring licenses for buying seats in MetLife Stadium's mezzanine.
The class-action suit was filed in Superior Court in Hackensack on Friday by an attorney for longtime Jets fans James T. Gengo of Trumbull, CT, who says he was required to pay $8,000 for personal seat licenses before he could buy two mid-level seats at the stadium before it opened in 2010.
The Jets rendered that outlay for him and more than 1,000 fellow fans "entirely or substantially worthless" -- violating consumer-protection laws in the process -- by announcing earlier this year that season tickets in his section don't require a PSL anymore.
Gengo and his co-plaintiffs want their PSL money back -- plus what they had to lay out to bring their suit to court.
Like other sports teams, the Jets have required the PSLs as a money maker to help pay its cost toward the new stadium. Holders can resell the license for however much they choose.
The licenses started out at $25,000 a pop in the lower bowl but have decreased by more than 80% over the past eight years.
As an offset to the new approach, the Jets are allowing mezzanine (200s) level ticket holders to move to the lower level at no additional PSL cost. The team also dropped the cost of tickets in the end zone 200s from $130 to $95 for next season.
Click here to sign up for Daily Voice's free daily emails and news alerts.


text:
Online Contact Management Software enables a company to easily sort, organise and manage their contacts, be they employee details or current prospects or leads. Using a Contact Management Software package can help to keep lists of contact details updated and in one unified area that is specifically designated for that type of information, instead of contact details being kept in separate formats across the company. The Contact Management Software here is offered under the SaaS (Software as a Service) model, meaning that the software is web based, hosted on the Cloud and can be accessed when needed through a client or web browser. If you're looking for similar online software like Contact Management Software, consider our Lead Management or Proposal Management Software categories.
If simplicity is just as important to you as feature set then look no further, we are your project management solution. We understand that real value isn't how much our software can do but more so how much we can empower you, the customer to do. Whether it's Projects, Tasks, Time or collaboration across teams, we do it all in one place, one view.
47 Reviews | Last reviewed on Sunday, 09 Nov 2014
25 Reviews
8 Reviews
3 Reviews
1 Review
Be first to write a review